TOPCON
TOPCON
Topcon announced the delivery of its 10,000th OCT device in late 2016 , and saw the FDA approval of its new 3D OCT-1 Maestro System .
“ A new standard of clinical utility by combining a high resolution colour non-mydriatic retinal camera with the latest Spectral Domain OCT technology ,” Topcon detailed in a release .
“ The rotating touch panel and fully automated ( alignment , focus and capture ) operation make the 3D OCT-1 Maestro the perfect diagnostic solution for even the smallest clinical practice .”
The company held its first international Swept Source OCT & Angiography Conference in Madrid Spain on Feb . 10-11 , 2017 , as the inaugural event dedicated to Swept Source OCT & Swept Source OCT Angiography .
The event featured presentations from leading ophthalmologists on a variety of topics , including recent advances in the field of Swept Source OCT , as well as its diagnostic uses for diabetic retinopathy , macular degeneration , glaucoma , tumours and more .
ZEISS
The medical technology group ZEISS received its US FDA Clearance for its new Swept-Source OCT imaging machine , the PLEX Elite 9000 in late 2016 .
“ This powerful , cutting-edge Swept-Source OCT and OCT Angiography platform was designed for advanced retina research and is at the core of the Advanced Retina Imaging ( ARI ) Network ,” ZEISS said in a media release .
The ARI Network is focused on exploring new clinical applications for the diagnosis and treatment of eye disease and advancing OCT innovation to benefit patients in the coming years ARI Network , a unique global consortium of clinicians and scientists from around the world , are working at the forefront of retinal disease research . The company says the US FDA approval will allow the ARI Network to more easily enroll patients and may facilitate faster research approval .
The wide-field , high-resolution visualization provided by the new ZEISS technology “ expands clinicians ’ ability to examine the critical microstructures and microvasculature of the posterior segment at any depth of interest from vitreous to sclera .”
The company said the new piece of equipment is a breakthrough it their quest to achieve better and faster imaging of the retina and choroid .
“ By imaging deeper and in greater detail than ever before , we will further our understanding of the retina and choroid , and greatly facilitate clinical trial investigations into different diseases ,” says Dr . Rosenfeld , Chairman of the ARI Network . “ This collaboration between the retina experts in the ARI Network and the engineers and scientists at ZEISS is vital to the advancement of retinal and choroidal imaging and scientific discovery .”
36 Optical Prism | March 2017